Last update 13 Mar 2026
Harbin Pharmaceutical Group Bioengineering Co. Ltd.

Harbin Pharmaceutical Group Bioengineering Co. Ltd.

Subsidiary Company|1995|Heilongjiang Sheng, China|
www.hayaobio.net

Overview

Tags

Hemic and Lymphatic Diseases
Neoplasms
Immune System Diseases
Biosimilar
Interferons
Colony-stimulating factors

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases3
Neoplasms1
Immune System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Biosimilar3
Colony-stimulating factors2
Interferons1
Top 5 TargetCount
EPO receptor(Erythropoietin receptor)1
CSF-2R(Granulocyte-macrophage colony-stimulating factor receptor)1
IFNAR(Interferon alpha/beta receptor)1

Related

3
Drugs associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Recombinant human erythropoietin (CHO Cell), Harbin Pharmaceutical Group Bioengineering(Harbin Pharmaceutical Group Co., Ltd.)
Target
EPO receptor
Mechanism
EPO receptor agonists
Active Org.
Harbin Pharmaceutical Group Bioengineering Co. Ltd.Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Originator Org.
Harbin Pharmaceutical Group Co., Ltd.Harbin Pharmaceutical Group Co., Ltd.
Active Indication
Anemia
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date19 Oct 2005
Recombinant human granulocyte/macrophage colony-stimulating factor(Harbin Pharmaceutical Group Co., Ltd.)
Target
CSF-2R
Mechanism
CSF-2R stimulants
Active Org.
Harbin Pharmaceutical Group Bioengineering Co. Ltd.Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Originator Org.
Harbin Pharmaceutical Group Co., Ltd.Harbin Pharmaceutical Group Co., Ltd.
Active Indication
Leukopenia [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jan 1999
Recombinant human interferon alfa-2b(Harbin Pharmaceutical Group Co., Ltd.)
Target
IFNAR
Mechanism
IFNAR agonists [+2]
Active Org.
Harbin Pharmaceutical Group Bioengineering Co. Ltd.Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Originator Org.
Harbin Pharmaceutical Group Co., Ltd.Harbin Pharmaceutical Group Co., Ltd.
Active Indication
Condylomata Acuminata [+6]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jan 1996
1
Clinical Trials associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
CTR20255237
/ Active, not recruitingNot Applicable
克立硼罗软膏人体生物等效性试验
[Translation] Human bioequivalence test of criboroxate ointment
100 Clinical Results associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Login to view more data
100 Deals associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Login to view more data
100 Translational Medicine associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
3
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free